• Gilead Sciences (NasdaqGS:GILD) plans to acquire Arcellx in a deal valued at up to $7.8b.
• The transaction is aimed at expanding Gilead's cancer cell therapy pipeline, especially in multiple myeloma.
• The deal is expected to close in the second quarter of 2026, subject to customary approvals.

Gilead Sciences, trading at $148.56, has seen a 22.2% return year to date and a 33.5% return over the past year. Over longer periods, the stock has recorded a 105.0% return over three years and 178.0% over five years, which places this planned acquisition in the context of an already substantial track record. For investors watching NasdaqGS:GILD, this move comes in addition to the company’s established presence in antiviral therapies and oncology.

The Arcellx deal adds a CAR T cell candidate for multiple myeloma, co developed with Kite Pharma, into Gilead's pipeline. This may influence how the company allocates capital and prioritises research over the next few years. As the acquisition progresses toward an expected completion in the second quarter of 2026, investors may want to track regulatory milestones, integration plans and any updates on clinical progress for the Arcellx programs.

Stay updated on the most important news stories for Gilead Sciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Gilead Sciences.

This planned Arcellx acquisition pushes Gilead further into cancer cell therapy, an area where it competes with companies such as Bristol Myers Squibb and Johnson & Johnson. For up to US$7.8b, Gilead is aiming to deepen its presence in multiple myeloma through an investigational CAR T treatment already co developed with its Kite unit. For you as an investor, the key question is whether the potential long term contribution from this program and broader cell therapy know how will justify the sizable outlay and integration work. The move also sits alongside Gilead’s efforts in HIV, including the bictegravir and lenacapavir combination data, suggesting the company is trying to balance its established antiviral base with higher risk oncology assets. That mix can diversify earnings sources, but it can also increase execution risk, because cell therapies can be costly to develop, manufacture and commercialize. How effectively Gilead aligns Arcellx’s pipeline with Kite’s existing platform, and how regulators and payers respond to any approved products, will be important for assessing the return on this deal over time.

How This Fits Into The Gilead Sciences Narrative

• The deal lines up with the narrative that Gilead is broadening its oncology and cell therapy portfolio to reduce reliance on HIV therapies and build new long term revenue streams.
• It also increases execution risk in diversification, because success now depends more on complex cell therapy programs alongside existing launches such as Trodelvy and Livdelzi.
• The specific contribution of Arcellx’s multiple myeloma candidate and related programs does not appear to be broken out in the existing narrative, so the eventual revenue and margin impact may not yet be fully reflected in those assumptions.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Gilead Sciences to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts have flagged at least one risk around Gilead’s financial position, and a large acquisition can add to concerns about debt levels or future capital allocation flexibility.
• ⚠️ Cell therapy programs can face clinical, regulatory and reimbursement hurdles, so the Arcellx deal may not deliver the outcomes implied by its size if trials or uptake fall short.
• 🎁 The company is viewed as good value based on some models, trading at a discount to certain fair value estimates. That may provide some scope if the acquisition and pipeline execution progress as planned.
• 🎁 Gilead pays a dividend and has seen very large recent earnings growth, while analysts also expect earnings to grow in the years ahead. This can support the case for funding and integrating new oncology assets.

What To Watch Going Forward

From here, you may want to track the regulatory timeline and clinical updates for Arcellx’s multiple myeloma program, alongside any disclosures on how Gilead plans to integrate Arcellx with Kite. Keep an eye on management commentary about deal financing, debt and capital returns, because those signals will show how the acquisition fits with broader cash flow priorities. It is also worth monitoring competitive moves in cell therapy from peers such as Novartis and Bristol Myers Squibb, as shifts in efficacy, safety or pricing expectations across the group can influence how attractive Gilead’s expanded pipeline looks. Finally, watch for any updates to earnings guidance or long term targets that reference Arcellx, as that will give clearer visibility on how management sees this transaction feeding into future profitability.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Gilead Sciences, head to the community page for Gilead Sciences to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.